NYMXF (Nymox Pharmaceutical) EBITDA Margin %: 0.00% (As of Dec. 2024)


What is Nymox Pharmaceutical EBITDA Margin %?

Nymox Pharmaceutical NYMXF +9.09% EBITDA Margin % is 0.00% as of Dec. 2024.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nymox Pharmaceutical's EBITDA for the three months ended in Dec. 2024 was $-0.77 Mil. Nymox Pharmaceutical's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Nymox Pharmaceutical's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.

Nymox Pharmaceutical  (OTCPK:NYMXF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Nymox Pharmaceutical EBITDA Margin % Related Terms

Nymox Pharmaceutical EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Nymox Pharmaceutical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nymox Pharmaceutical EBITDA Margin % Chart

Nymox Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -228,580.00 0.00 0.00 0.00 0.00

Nymox Pharmaceutical Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 105,540.00 0.00 0.00

NYMXF vs LYRA, RNAZ, TOVX: EBITDA Margin % Comparison

For the Biotechnology subindustry, Nymox Pharmaceutical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nymox Pharmaceutical EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's EBITDA Margin % falls into.


Nymox Pharmaceutical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Nymox Pharmaceutical's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-4.265/0
= %

Nymox Pharmaceutical's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-0.771/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Nymox Pharmaceutical (NYMXF) has a EBITDA Margin % of 0.00% as of Dec. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nymox Pharmaceutical and its competitors.
Is Nymox Pharmaceutical's EBITDA Margin % too high?
Nymox Pharmaceutical's current EBITDA Margin % is 0.00%.
How does Nymox Pharmaceutical's EBITDA Margin % compare to LYRA and RNAZ?
Nymox Pharmaceutical's EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nymox Pharmaceutical and its competitors. Nymox Pharmaceutical's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nymox Pharmaceutical stock overvalued right now?
Nymox Pharmaceutical (NYMXF) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nymox Pharmaceutical (NYMXF), the current EBITDA Margin % is 0.00% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nymox Pharmaceutical Business Description

Address Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and low-grade localized prostate cancer. The company also has an extensive patent portfolio covering its investigational drug as well as other therapeutic and diagnostic indications. It also has U.S. and patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The company operates in one reportable segment, focused on researching and developing products for the aging population.